Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Preditive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Guselkumab and the Development of the Concentration-response Curve of Guselkumab for Psoriasis Patients.

NCT04080648 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT04080648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04080648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Preditive Value of Early Serum Trough Concentrations and Anti-drug Antibodies of Guselkumab and the Development of the Concentration-response Curve of Guselkumab for Psoriasis Patients.
Lead sponsor
University Hospital, Ghent
Phase
Phase 4
Overall status
Completed
Start date
June 27, 2018
Completion date
December 31, 2023
Enrollment
79 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis vulgaris